Rodrigo B Interiano1, M Beth McCarville2, Noel Delos Santos3, Shenghua Mao4, Jianrong Wu4, Jeffrey S Dome5, Kathleen Kieran6, Mark A Williams7, Rachel C Brennan8, Matthew J Krasin9, Daniel M Green10, Andrew M Davidoff11. 1. Department of Surgery, St. Jude Children's Research Hospital, Memphis, TN; Department of Surgery, University of Tennessee Health Science Center, Memphis, TN. 2. Department of Diagnostic Imaging, St. Jude Children's Research Hospital, Memphis, TN. 3. Department of Pediatrics, University of Tennessee Health Science Center, Memphis, TN. 4. Department of Biostatistics, St. Jude Children's Research Hospital, Memphis, TN. 5. Department of Oncology, Children's National Medical Center, Washington, DC. 6. Department of Urology, Seattle Children's Hospital, Seattle, WA. 7. Division of Pediatric Urology, Levine Children's Hospital, Charlotte, NC. 8. Department of Pediatrics, University of Tennessee Health Science Center, Memphis, TN; Department of Oncology, St. Jude Children's Research Hospital, Memphis, TN. 9. Department of Radiation Oncology, St. Jude Children's Hospital, Memphis, TN. 10. Department of Epidemiology and Cancer Control, St. Jude Children's Research Hospital, Memphis, TN. 11. Department of Surgery, St. Jude Children's Research Hospital, Memphis, TN; Department of Surgery, University of Tennessee Health Science Center, Memphis, TN. Electronic address: andrew.davidoff@stjude.org.
Abstract
OBJECTIVES: The purpose of this study was to perform a comprehensive assessment of long-term renal function in patients treated at our institution for synchronous bilateral Wilms tumor (BWT) and to determine the optimal method for estimating glomerular filtration rate (eGFR). METHODS: Surgical approach, adjuvant therapy, and pathology reports were reviewed for patients with at least six months follow-up from definitive surgery. eGFRs, as assessed by the Schwartz and Chronic Kidney Disease in Children (CKiD) formulas, were compared to measured GFR (mGFR) determined by 99mTc-DTPA scanning. Urine studies, including microalbumin, β-microglobulin, and FENa were also reviewed. RESULTS: Forty-two patients were identified. Of 36 living patients, 28 (77.8%) had greater than 6months follow-up, with a median overall follow-up of 5.2years (range: 1.4-13.4). The median mGFR was 97mL/min/1.73m2, while the median eGFRSchwartz and eGFRCKiD were 103.3mL/min/1.73m2 and 79.7mL/min/1.73m2, respectively, (p=0.13 and p=0.75, compared to mGFR). Eleven (39.3%) patients had at least one abnormal urine study (microalbumin >30μg/g creatinine, n=3; β-2 microglobulin >133μg/g creatinine, n=9; FENa>1%, n=4). CONCLUSIONS: In our series, few patients had an abnormally low GFR. Neither method for estimating GFR gave a significantly different result from measured GFR, suggesting that the Schwartz equation is adequate, although specific urine tests may be more sensitive for detecting subtle renal dysfunction. LEVEL OF EVIDENCE: Level IV - retrospective case series with no comparison group.
OBJECTIVES: The purpose of this study was to perform a comprehensive assessment of long-term renal function in patients treated at our institution for synchronous bilateral Wilms tumor (BWT) and to determine the optimal method for estimating glomerular filtration rate (eGFR). METHODS: Surgical approach, adjuvant therapy, and pathology reports were reviewed for patients with at least six months follow-up from definitive surgery. eGFRs, as assessed by the Schwartz and Chronic Kidney Disease in Children (CKiD) formulas, were compared to measured GFR (mGFR) determined by 99mTc-DTPA scanning. Urine studies, including microalbumin, β-microglobulin, and FENa were also reviewed. RESULTS: Forty-two patients were identified. Of 36 living patients, 28 (77.8%) had greater than 6months follow-up, with a median overall follow-up of 5.2years (range: 1.4-13.4). The median mGFR was 97mL/min/1.73m2, while the median eGFRSchwartz and eGFRCKiD were 103.3mL/min/1.73m2 and 79.7mL/min/1.73m2, respectively, (p=0.13 and p=0.75, compared to mGFR). Eleven (39.3%) patients had at least one abnormal urine study (microalbumin >30μg/g creatinine, n=3; β-2 microglobulin >133μg/g creatinine, n=9; FENa>1%, n=4). CONCLUSIONS: In our series, few patients had an abnormally low GFR. Neither method for estimating GFR gave a significantly different result from measured GFR, suggesting that the Schwartz equation is adequate, although specific urine tests may be more sensitive for detecting subtle renal dysfunction. LEVEL OF EVIDENCE: Level IV - retrospective case series with no comparison group.
Authors: Najat C Daw; David Gregornik; John Rodman; Neyssa Marina; Jianrong Wu; Larry E Kun; Jesse J Jenkins; Valerie McPherson; Judith Wilimas; Deborah P Jones Journal: Eur J Cancer Date: 2008-11-06 Impact factor: 9.162
Authors: Andrew M Davidoff; Dana W Giel; Deborah P Jones; Jesse J Jenkins; Matthew J Krasin; Fredric A Hoffer; Mark A Williams; Jeffrey S Dome Journal: Cancer Date: 2008-05-01 Impact factor: 6.860
Authors: Andrew M Davidoff; Rodrigo B Interiano; Lynn Wynn; Noel Delos Santos; Jeffrey S Dome; Daniel M Green; Rachel C Brennan; M Beth McCarville; Matthew J Krasin; Kathleen Kieran; Mark A Williams Journal: Ann Surg Date: 2015-10 Impact factor: 12.969
Authors: David I Chu; Abdulla M Ehlayel; Jill P Ginsberg; Kevin E Meyers; Maryjane Benton; Melissa Thomas; Claire Carlson; Thomas F Kolon; Gregory E Tasian; Jason H Greenberg; Susan L Furth; Michelle R Denburg Journal: J Pediatr Date: 2020-12-05 Impact factor: 4.406
Authors: Esmee Cm Kooijmans; Arend Bökenkamp; Nic S Tjahjadi; Jesse M Tettero; Eline van Dulmen-den Broeder; Helena Jh van der Pal; Margreet A Veening Journal: Cochrane Database Syst Rev Date: 2019-03-11
Authors: Stephanie B Dixon; Kari L Bjornard; Nicole M Alberts; Gregory T Armstrong; Tara M Brinkman; Wassim Chemaitilly; Matthew J Ehrhardt; Israel Fernandez-Pineda; Lisa M Force; Todd M Gibson; Daniel M Green; Carrie R Howell; Sue C Kaste; Anne C Kirchhoff; James L Klosky; Kevin R Krull; John T Lucas; Daniel A Mulrooney; Kirsten K Ness; Carmen L Wilson; Yutaka Yasui; Leslie L Robison; Melissa M Hudson Journal: CA Cancer J Clin Date: 2018-01-29 Impact factor: 508.702